Skip to content

Nanoparticle and Peptide Therapeutics Drug Delivery Beyond Injections Emerging GLP-1 Indications GLP-1 Science and Mechanisms GLP-1 Side Effects and Patient Experience Nose-to-Brain (N2B) Delivery Features

/

Nanoparticle and Peptide Therapeutics Drug Delivery Beyond Injections Emerging GLP-1 Indications GLP-1 Science and Mechanisms GLP-1 Side Effects and Patient Experience Nose-to-Brain (N2B) Delivery Features

/

About

glpletter

A blog and newsletter on Intranasal and nose-to-brain drug delivery science, GLP-1 biology, therapeutics, and market landscape.

What we cover

Nanoparticle and Peptide Therapeutics
Drug Delivery Beyond Injections
Emerging GLP-1 Indications
GLP-1 Science and Mechanisms
GLP-1 Side Effects and Patient Experience
Nose-to-Brain (N2B) Delivery
Features

Contributors

Tobias Wrenfield
Mei-Lin Tso
Amara Osei-Bonsu
Priya Subramaniam

A blog and newsletter on Intranasal and nose-to-brain drug delivery science, GLP-1 biology, therapeutics, and market landscape.

Sections

Nanoparticle and Peptide Therapeutics
Drug Delivery Beyond Injections
Emerging GLP-1 Indications
GLP-1 Science and Mechanisms
GLP-1 Side Effects and Patient Experience
Nose-to-Brain (N2B) Delivery

glpletter

Latest
About
RSS Feed

© 2026 glpletter

All rights reserved